^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)

    i
    Other names: LRIG3, Leucine-rich repeats and immunoglobulin-like domains protein 3, LIG3, FLJ90440, KIAA3016
    8d
    LRIG3 suppresses hypoxia-induced vasculogenic mimicry in glioma by promoting the ubiquitination and degradation of Snail2. (PubMed, Cell Stress Chaperones)
    LRIG3 inhibits hypoxia-induced VM in glioma by facilitating the proteasomal degradation of Snail2 via ubiquitination.
    Journal
    |
    LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) • SNAI2 (Snail Family Transcriptional Repressor 2)
    4ms
    LRIG1-3 in gliomas: LRIG1 protein expression decreased in higher grade gliomas. (PubMed, Oncotarget)
    LRIG3 mRNA expression, in contrast, was significantly higher in grade II gliomas compared to surrounding control tissue, whereas chemotherapy did not significantly affect expression levels in glioblastoma. Our results reinforce suggestions that LRIG1-3 could function as diagnostic markers and therapeutic targets in the treatment of gliomas.
    Journal
    |
    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • LRIG2 (Leucine Rich Repeats And Immunoglobulin Like Domains 2) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    8ms
    Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma. (PubMed, JCO Precis Oncol)
    CDK4 amplification is a potential genetic biomarker to identify patients who may derive prolonged benefit from bevacizumab.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • CDK4 (Cyclin-dependent kinase 4) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • DDIT3 (DNA-damage-inducible transcript 3) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    |
    EGFR amplification
    |
    Avastin (bevacizumab)
    over1year
    Whole exome sequencing of human papillomavirus-related multiphenotypic sinonasal carcinoma: a case report. (PubMed, Front Oncol)
    This is the first report of WES analysis of an HMSC, in this case associated with HPV type 35. The detected mutation in EP300 and the overexpression of MYB may serve as molecular targets for personalized therapy.
    Journal
    |
    EP300 (E1A binding protein p300) • SOX10 (SRY-Box 10) • TP63 (Tumor protein 63) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) • ZNF609 (Zinc Finger Protein 609)
    |
    EP300 mutation
    over2years
    MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT (CTOS 2023)
    This series represents the largest cohort of multi-omic characterization of ESS. Our data confirmed the characteristic presence of JAZF1:SUZ12 fusions in LG-ESS. However, this fusion was also found in HG-ESS cases with retention of ER and PR expression.
    Real-world evidence • Clinical • Tumor mutational burden • MSi-H Biomarker • Real-world • Stroma
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler) • BCOR (BCL6 Corepressor) • NUTM2B (NUT Family Member 2B) • HMGA2 (High mobility group AT-hook 2) • JAZF1 (JAZF Zinc Finger 1) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
    |
    TP53 mutation • TMB-H • MSI-H/dMMR • ER positive + PGR positive • ATRX mutation • PGR positive • BCOR mutation • PGR expression
    |
    MI Tumor Seek™
    3years
    Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth. (PubMed, Cell Death Dis)
    Our study revealed vital molecular crosstalk between GBM tumor cells and TAMs. Glioma cells mediated the M2 polarization of TAM through the sLRIG3-NETO2 pathway and inhibited the progression of GBM, suggesting that sLRIG3-NETO2 may be a potential target for GBM treatment.
    Journal
    |
    ADAM17 (ADAM Metallopeptidase Domain 17) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    almost4years
    Age as a factor in the molecular landscape and the tumor-microenvironmental signature of osteosarcoma. (ASCO 2022)
    To the best of our knowledge, this study represents the largest cohort of molecularly characterized OS. Age-associated differences in the genetic landscape and TME composition, including increased gene amplifications observed in younger patients and decreased B-cell abundance in older patients, might suggest fundamental underlying molecular and biological differences.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • KMT2D (Lysine Methyltransferase 2D) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler) • CCND3 (Cyclin D3) • FLCN (Folliculin) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) • TFEB (Transcription Factor EB 2) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
    |
    PD-L1 expression • TP53 mutation • PIK3CA mutation • PTEN mutation
    |
    MI Tumor Seek™
    almost4years
    The fusion gene landscape in Chinese patients with non-small cell lung cancer (AACR 2022)
    We conducted a comprehensive review of fusion genes in Chinese patients with NSCLC. With the exception of common gene fusions, we found three cases of rare fusion mutations, which help to understand the potential pathogenic mechanisms of NSCLC and translate into therapeutic applications.
    Clinical
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • CD74 (CD74 Molecule) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin) • KLC1 (Kinesin light chain 1) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    |
    NTRK1 fusion • RET fusion • ALK fusion • ROS1 fusion • FGFR3 fusion
    4years
    Prognostic significance of LRIG2 and LRIG3 proteins in urothelial bladder carcinoma. (PubMed, J Immunoassay Immunochem)
    LRIG3 has the dominant role even if it coexists with LRIG2. The role of LRIG2 remains to be further investigated.
    Journal
    |
    LRIG2 (Leucine Rich Repeats And Immunoglobulin Like Domains 2) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    almost5years
    circ_LRIG3 contributes to the progression of hepatocellular carcinoma by elevating RNF38 via sponging miR-449a. (PubMed, Gen Physiol Biophys)
    RNase R assay and Actinomycin D assay were performed to analyze the characteristics of circ_LRIG3...In addition, circ_LRIG3 silencing might inhibit the Smad2/3 pathway. circ_LRIG3 facilitated HCC progression by modulation of miR-449a/LRIG3 axis, which might provide a novel method for HCC therapy.
    Journal
    |
    CDH1 (Cadherin 1) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    |
    dactinomycin
    almost5years
    The Prognostic Role of LRIG Proteins in Endometrial Cancer. (PubMed, Cancers (Basel))
    Our results show that LRIG3 expression might be a prognostic factor in EC. The role of LRIG1 and LRIG2 expression remains to be further investigated.
    Journal
    |
    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • LRIG2 (Leucine Rich Repeats And Immunoglobulin Like Domains 2) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    almost5years
    LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma. (PubMed, Front Oncol)
    Notably, LRIG3 had a significant negative correlation with VEGFA expression in glioma tissues. Taken together, our results suggest that LRIG3 is a novel regulator of glioma angiogenesis and may be a promising option for developing anti-angiogenic therapy.
    Journal
    |
    LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    |
    VEGFA expression